Abstract
The APOE genotype is a known susceptibility factor for Alzheimer’s disease (AD). It is apparent that the presence of the APOE ε40 allele increases the risk for developing AD, lowers the age of onset in AD, and may influence the pathological burden seen in AD. In this study, we asked whether BACE1 levels differ by APOE genotype in the AD and non-demented (ND) brain. We isolated mid-frontal cortex (MFC) and mid-temporal cortex (MTC) from post-mortem ND and AD subjects that were APOE ε3/3, ε3/4, ε4/4 carriers. All AD subjects met NINDS-ADRDA and NIA-Reagan criteria for a diagnosis of AD. The MFC and MTC were homogenized and the lysates underwent ELISA and Western blotting for BACE1. The ELISA revealed that total BACE1 levels were lower in the MFC of AD compared to ND subjects. Furthermore, in APOE ε4 carriers BACE1 levels were lower than ε3/3 carriers in the ND frontal cortex. No difference in BACE1 levels was observed in AD MFC and in ND and AD MTC tissues. The ELISA results were confirmed by Western blotting. Our data suggest that brain BACEl levels may be influenced by the apolipoprotein E genotype before the onset of AD, providing an alternative explanation for the lower amyloid beta 42 levels in CSF in ND and AD subjects.
Keywords: Alzheimer’s disease, APOE, BACE1, brain, ELISA, frontal cortex
Current Alzheimer Research
Title:BACE1 Levels by APOE Genotype in Non-Demented and Alzheimer’s Post-Mortem Brains
Volume: 10 Issue: 3
Author(s): Boris Decourt, Amanda Gonzales, Thomas G. Beach, Michael Malek-Ahmadi, Aaron Walker, Lucia Sue, Douglas G. Walker and Marwan N. Sabbagh
Affiliation:
Keywords: Alzheimer’s disease, APOE, BACE1, brain, ELISA, frontal cortex
Abstract: The APOE genotype is a known susceptibility factor for Alzheimer’s disease (AD). It is apparent that the presence of the APOE ε40 allele increases the risk for developing AD, lowers the age of onset in AD, and may influence the pathological burden seen in AD. In this study, we asked whether BACE1 levels differ by APOE genotype in the AD and non-demented (ND) brain. We isolated mid-frontal cortex (MFC) and mid-temporal cortex (MTC) from post-mortem ND and AD subjects that were APOE ε3/3, ε3/4, ε4/4 carriers. All AD subjects met NINDS-ADRDA and NIA-Reagan criteria for a diagnosis of AD. The MFC and MTC were homogenized and the lysates underwent ELISA and Western blotting for BACE1. The ELISA revealed that total BACE1 levels were lower in the MFC of AD compared to ND subjects. Furthermore, in APOE ε4 carriers BACE1 levels were lower than ε3/3 carriers in the ND frontal cortex. No difference in BACE1 levels was observed in AD MFC and in ND and AD MTC tissues. The ELISA results were confirmed by Western blotting. Our data suggest that brain BACEl levels may be influenced by the apolipoprotein E genotype before the onset of AD, providing an alternative explanation for the lower amyloid beta 42 levels in CSF in ND and AD subjects.
Export Options
About this article
Cite this article as:
Decourt Boris, Gonzales Amanda, G. Beach Thomas, Malek-Ahmadi Michael, Walker Aaron, Sue Lucia, G. Walker Douglas and N. Sabbagh Marwan, BACE1 Levels by APOE Genotype in Non-Demented and Alzheimer’s Post-Mortem Brains, Current Alzheimer Research 2013; 10 (3) . https://dx.doi.org/10.2174/1567205011310030010
DOI https://dx.doi.org/10.2174/1567205011310030010 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Bioengineering, Clinical and Therapeutical Trends in Transcatheter Aortic Valve Implantation
Current Pharmaceutical Design Homocysteine Enhances Transmigration of Rat Monocytes through a Brain Capillary Endothelial Cell Monolayer via ICAM-1
Current Neurovascular Research East Meets West in the Search for Alzheimers Therapeutics - Novel Dimeric Inhibitors from Tacrine and Huperzine A
Current Alzheimer Research Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Potential for Stem Cells Therapy in Alzheimer’s Disease: Do Neurotrophic Factors Play Critical Role?
Current Alzheimer Research Proteoglycans and Glycosaminoglycans in Misfolded Proteins Formation in Alzheimer's Disease
Protein & Peptide Letters Cortical Consequences of HIV-1 Tat Exposure in Rats are Enhanced by Chronic Cocaine
Current HIV Research Complement and Microglia in the Neuropathogenesis of HIV Infection: Pro- and Anti-Inflammatory Aspects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Future Targeted Disease Modifying Drugs for Alzheimer's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Assessment of Persistent, Bioaccumulative and Toxic Organic Environmental Pollutants in Liver and Adipose Tissue of Alzheimer’s Disease Patients and Age-matched Controls
Current Alzheimer Research Low Baseline Urine Creatinine Excretion Rate Predicts Poor Outcomes among Critically Ill Acute Stroke Patients
Current Neurovascular Research GABAergic Modulation in Diabetic Encephalopathy-Related Depression
Current Pharmaceutical Design Preeclampsia and the Future Development of Cardiovascular Disease: A Review
Current Women`s Health Reviews Lithium and its Neuroprotective and Neurotrophic Effects: Potential Treatment for Post-Ischemic Stroke Sequelae
Current Drug Targets Inhibition of GSK3 Dependent Tau Phosphorylation by Metals
Current Alzheimer Research Commentary [Research Highlights : Neurotrophic Factor Treatment of Neurological Disorders: The Benefits of a Pleiotropic Treatment Approach]
CNS & Neurological Disorders - Drug Targets Current and Future Therapeutic Strategies for Parkinsons Disease
Current Pharmaceutical Design Cardiovascular Comorbidities of COPD: When Do they Occur and How are they Managed?
Current Respiratory Medicine Reviews Role of Psychiatrists in the Diagnosis and Management of Alzheimer's Disease “Revisited”: A Review and Clinical Opinion
Current Psychiatry Reviews The Hypothesis of the Catalytic Action of Nucleic Acid on the Conversion of Prion Protein
Protein & Peptide Letters